Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Oct 10, 2012 (14 years ago)

QUETIAPINE Fumarate Tablets 25mg 100 Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Test Requirements: During analysis of long term stability studies at 3 months time point, an OOS was reported for Quetiapine Fumarate Tablets, 25 mg.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

QUETIAPINE Fumarate Tablets 25mg 100 Tablets (10x10) Blister card, Rx, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 68084-530-01

Affected NDC 68084-0530-01

Compare with the code on your package — it is the most precise check available.

Drug: Quetiapine Category: Mental Health Medication

Recalling firm
American Health Packaging
NDC code
68084-530-01
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-802-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Quetiapine recalls

See all
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1002-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1001-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-1000-2020
Class III · Low risk

Quetiapine Fumarate Extended-Release Tablets

Labeling; Incorrect or Missing Package Insert: Product was packaged with the package insert for Quetiapine Fumarate Tablets not Quetiapine Fumarate Extended-Release Tablets.

Terminated Labeling / mix-up The Harvard Drug Group D-0999-2020

Other recalls by American Health Packaging

All 2012 recalls
Class III · Low risk

Nitrofurantoin Capsules

Failed Dissolution Specifications: Nitrofurantoin Capsules recalled due to dissolution failure at 0-time of the repackaged lot. Drug release results were above specification at 0-time.

Terminated Dissolution failure American Health Packaging NDC 68084-446-11 D-0880-2022